The firm will use the funds to continue expanding its technology into food and agriculture testing, in addition to growing its cannabis testing business.

Tempus Labs researchers said they could match more than 40 percent of patients to a targeted treatment and 77 percent of patients to a relevant clinical trial.

The partners will more thoroughly connect Protein Metrics' software suite and Sciex's high-resolution accurate mass (HRAM) spectrometry systems.

The WGS analysis placed the triple-negative breast cancers into three groups, each of which had different treatment responses and prognoses.

The director of the Biomedical Advanced Research and Development Authority has launched two new funding programs in the past three years.

The early-stage genomics-based trials suggest tumor sequence can be informative for late-stage cancers, as an ESMO group seeks clinically meaningful translation.

On Twitter, University of California, Berkeley's Rasmus Nielsen says an error was uncovered in the analysis he and a colleague performed.

Researchers in the UK are bracing for Brexit by stockpiling some supplies, according to the New Scientist.

Arrests have been made and charges filed in connection with a genetic testing fraud scheme, Reuters reports.

In PLOS this week: genetic analysis of Iranian ethnic groups, genome-wide methylation analysis of cataracts among giant pandas, and more.

The firm has a 180-day grace period in which to regain compliance, by maintaining a $1.00 minimum closing bid price for at least 10 consecutive business days.

The T2 Biosystems T2Resistance Panel for genotypic antibiotic resistance marker testing is now available as a research use only test in the US. The panel uses the firm's T2Dx instrument and identifies 13 genes conferring resistance to common empiric antibiotic therapies, such as carbapenems, vancomycin, and penicillin, directly from whole blood within three to five hours. The panel received breakthrough device designation from the US Food and Drug Administration earlier this year and is on track to receive CE mark by the end of 2019.

The new analysis has confirmed earlier evidence that patients with high Oncotype DX risk scores appear to benefit significantly from added chemotherapy.

A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.

The partners will codevelop software for both small and large variant detection and Illumina will create hardware-accelerated versions for its Dragen platform.

When used together, ThyGeNext and ThyraMir combine next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier.

Last week, GenomeWeb readers were most interested in Illumina's plan to lay off 58 employees in California and in funding for a new human genome reference program.

The Swiss company markets the WAVE system, a waveguide interferometry-based instrument for studying molecular interactions in real time.

The team identified six independent DNA methylation blocks that could potentially help to predict the formation of central nervous system metastases in lung cancer.

The firm disclosed to the state of California that it plans to lay off 42 employees in San Diego and 16 employees in Foster City.

The results of the study, which involved more than 47,000 MS patients and 68,000 unaffected controls, explain almost half of the disease's estimated heritability.

Gathering last week in Australia, the community continued its years-long push towards increased clinical relevance and integration with other omics disciplines.

Personal Genomics alleged that PacBio tried to sublicense the patent-in-suit in the years prior to its launch of the Sequel sequencing platform.

The researchers hope to eventually develop a point-of-care assay to detect conditions that lead to high-risk pregnancies before symptoms occur.